Latest news with #ASCVD
Medscape
10-07-2025
- Health
- Medscape
Lipoprotein Exposure Before 40 Predicts Future Heart Risk
TOPLINE: For adults younger than 40 years, higher cumulative exposure to atherogenic lipoprotein particles — apolipoprotein B, low-density lipoprotein particles, and triglyceride-rich lipoprotein particles — was associated with a significant increase in the risk for atherosclerotic cardiovascular disease (ASCVD) after 40 years of age. METHODOLOGY: Researchers analyzed prospective data from a population-based cohort study of US adults (n = 5115; 55% women) to examine whether exposure to atherogenic lipoprotein particles during early adulthood was linked to ASCVD in midlife. They evaluated the levels of atherogenic lipoprotein particles — apolipoprotein B, low-density lipoprotein particles, and triglyceride-rich lipoprotein particles — in 4366 participants aged 18-40 years to calculate the cumulative exposure over 22 years. ASCVD events — fatal and nonfatal myocardial infarction and stroke — occurring after age 40 were tracked over a mean follow-up of 19.3 years. TAKEAWAY: Each SD increase in cumulative exposure to atherogenic lipoprotein particles was associated with a 28%-30% higher risk for ASCVD after age 40; adjusted hazard ratios were 1.30 (95% CI, 1.15-1.46) for apolipoprotein B, 1.28 (95% CI, 1.13-1.44) for low-density lipoprotein particles, and 1.28 (95% CI, 1.13-1.45) for triglyceride-rich lipoprotein particles. The risk for ASCVD increased notably when usual exposure exceeded 75 mg/dL/y for apolipoprotein B, 1000 nmol/L/y for low-density lipoprotein particles, and 135 nmol/L/y for triglyceride-rich lipoprotein particles. The risk for ASCVD after age 40 was generally linear when each atherogenic lipoprotein particle was examined separately. IN PRACTICE: 'Data presented from the current analysis from one US-based cohort study of young adults offer potential clinical thresholds, rather than definitive cutoff values for clinical practice,' the researchers of the study noted. 'While clinical validation is needed, these values could serve as reasonable targets for untreated young adults, and achieving them may require both individual-level interventions — such as lifestyle modification and pharmacotherapy — as well as policy-level strategies, including subsidies for nutritious foods and public health initiatives to promote physical activity,' they added. SOURCE: This study was led by Alexander R. Zheutlin, MD, Northwestern University Feinberg School of Medicine, Chicago. It was published online on July 4, 2025, in the European Heart Journal. LIMITATIONS: Many clinical practices lacked the ability to measure specific subfractions of lipoprotein particles. Children were not included in this study, despite evidence of childhood exposure to lipid particles predicting heart disease risk in adult life. This study was not sufficiently powered to stratify risks based on race and gender. DISCLOSURES: The original cohort study was supported by the National Heart, Lung, and Blood Institute in collaboration with the University of Alabama, Northwestern University, University of Minnesota, and Kaiser Foundation Research Institute. One author reported receiving funding from the National Institutes of Health and personal fees from 3M. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
18-06-2025
- Business
- Yahoo
Verve Therapeutics Stock Soars as Eli Lilly Buys Gene-Editing Firm for $1.3B
Shares of Verve Therapeutics soared 75% Tuesday as Eli Lilly said it would acquire the gene-editing startup. The deal values Verve at about $1.3 billion, with some of Eli Lilly's potential payments dependent on certain trial milestones. Verve has an early stage clinical trial of a treatment to lower cholesterol and treat cardiovascular of Verve Therapeutics (VERV) skyrocketed 75% Tuesday morning after Eli Lilly (LLY) announced that it would acquire the gene-editing startup for about $1.3 billion. Eli Lilly said it will pay $10.50 per share to Verve shareholders initially, with a $3-per-share contingent value right (CVR) potentially paid out if Verve treats at least one patient with gene-editing medicine VERVE-102 for atherosclerotic cardiovascular disease (ASCVD) in a Phase 3 clinical trial within a decade of the deal's closing or termination of the CVR. The transaction is expected to close in the third quarter this year. VERVE-102 currently "is being evaluated in a Phase 1b clinical trial study and has been granted Fast Track designation by the U.S. Food and Drug Administration," Lilly said. "Verve was founded with one mission in mind: transform the treatment of cardiovascular disease from chronic care to a one-dose future," Verve CEO Dr. Sekar Kathiresan said. "In just seven years, our team has progressed three in vivo gene editing products, with two currently in the clinic. Now, we will take the next steps in the drug development journey together with an ideal strategic partner in Lilly." The Financial Times reported late Monday that the companies were close to a deal. Eli Lilly shares, which entered Tuesday up roughly 5% this year, were down less than 1% in recent trading. With today's sharp gains, Verve stock has nearly doubled in 2025. UPDATE—This article has been updated with the latest share price information. Read the original article on Investopedia
Miami Herald
17-06-2025
- Business
- Miami Herald
Eli Lilly Co. to buy gene-editing startup Verve to develop cardiac drugs
June 17 (UPI) --Eli Lilly and Company said Tuesday it will buy out Boston-based Verve Therapeutics Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac health drugs. Indianapolis-based Eli Lilly announced its definitive agreement to acquire Verge, a gene-editing startup, for up to $1.3 billion at $10.50 a share -- a premium of 67.5% at last closing -- with the goal to boost Verve's budding pipeline of medicine designed to target and treat a wide-range of cardiovascular-related health issues. "Lilly is eager to welcome our Verve colleagues to Lilly and continue the development of these promising potential new medicines aimed at improving outcomes for patients with cardiovascular disease and addressing the significant unmet medical need in this space," said Ruth Gimeno, Lilly's group VP for diabetes and metabolic research and development. Under the agreement terms, the transaction will not be subject to any financing conditions and will include a nearly $1 billion upfront payout plus a further $300 million based on certain clinical milestones. The deal is expected to close by this year's third quarter subject to conditions. Verve's medical treatment program, according to a Gimeno, could "shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment." Meanwhile, stock shares in Verve jumped 76% to over $11 in premarket trading Tuesday morning while Lilly stock value fell 1%. A years-long study from 2010-2022 released in November revealed how the number of dead via cardiovascular disease had surged among adults ages 25 to 64 living in rural areas. Verve uses a next gen type of gene editing which erases and rewrites a specific gene letter. Lilly's Gimeno says the Verve-102 program, which is currently in its Phase 1b clinal trial study and fast-tracked for FDA approval, "has the potential" to be the first "in vivo" gene editing therapy deployed to treat a broad population of patients seeking treatment for cardiac issues. 102 may be utilized for patients seeking treatment for heterozygous familial hypercholesterolemia (HeFH), which is a subset of ASCVD affecting 1 in 250 people. On Tuesday, Verve's chief noted how in just seven years that the Verve team had progressed three in vivo gene editing products with two currently in clinics. "Verve was founded with one mission in mind: transform the treatment of cardiovascular disease from chronic care to a one-dose future," said Verve Therapeutics co-founder and CEO Dr. Sekar Kathiresan. Copyright 2025 UPI News Corporation. All Rights Reserved.
UPI
17-06-2025
- Business
- UPI
Eli Lilly Co. to buy gene-editing startup Verve to develop cardiac drugs
Verve's medical treatment program could "shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment," one Eli Lilly official said. Photo by Julio César Velásquez Mejía June 17 (UPI) -- Eli Lilly and Company said Tuesday it will buy out Boston-based Verve Therapeutics Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac health drugs. Indianapolis-based Eli Lilly announced its definitive agreement to acquire Verge, a gene-editing startup, for up to $1.3 billion at $10.50 a share -- a premium of 67.5% at last closing -- with the goal to boost Verve's budding pipeline of medicine designed to target and treat a wide-range of cardiovascular-related health issues. "Lilly is eager to welcome our Verve colleagues to Lilly and continue the development of these promising potential new medicines aimed at improving outcomes for patients with cardiovascular disease and addressing the significant unmet medical need in this space," said Ruth Gimeno, Lilly's group VP for diabetes and metabolic research and development. Under the agreement terms, the transaction will not be subject to any financing conditions and will include a nearly $1 billion upfront payout plus a further $300 million based on certain clinical milestones. The deal is expected to close by this year's third quarter subject to conditions. Verve's medical treatment program, according to a Gimeno, could "shift the treatment paradigm for cardiovascular disease from chronic care to one-and-done treatment." Meanwhile, stock shares in Verve jumped 76% to over $11 in premarket trading Tuesday morning while Lilly stock value fell 1%. A years-long study from 2010-2022 released in November revealed how the number of dead via cardiovascular disease had surged among adults ages 25 to 64 living in rural areas. Verve uses a next gen type of gene editing which erases and rewrites a specific gene letter. Lilly's Gimeno says the Verve-102 program, which is currently in its Phase 1b clinal trial study and fast-tracked for FDA approval, "has the potential" to be the first "in vivo" gene editing therapy deployed to treat a broad population of patients seeking treatment for cardiac issues. 102 may be utilized for patients seeking treatment for heterozygous familial hypercholesterolemia (HeFH), which is a subset of ASCVD affecting 1 in 250 people. On Tuesday, Verve's chief noted how in just seven years that the Verve team had progressed three in vivo gene editing products with two currently in clinics. "Verve was founded with one mission in mind: transform the treatment of cardiovascular disease from chronic care to a one-dose future," said Verve Therapeutics co-founder and CEO Dr. Sekar Kathiresan.
Business Wire
17-06-2025
- Business
- Business Wire
Shareholder Alert: The Ademi Firm Investigates Whether Verve Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Verve (Nasdaq: VERV) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ or toll-free: 866-264-3995. There is no cost or obligation to you. In the tender offer transaction, shareholders of Verve will receive $10.50 per share in cash (an aggregate of approximately $1.0 billion) payable at closing, plus one non-tradeable contingent value right (CVR) per share that entitles the holder to receive up to an additional $3.00 per share, for a total potential consideration of up to $13.50 per share in cash without interest (an aggregate of up to approximately $1.3 billion). CVR holders would become entitled to receive the contingent payment upon the first patient being dosed with VERVE-102 for ASCVD in a U.S. Phase 3 clinical trial on or prior to the tenth anniversary of closing or termination of the CVR. Verve insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Verve by imposing a significant penalty if Verve accepts a competing bid. We are investigating the conduct of the Verve board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
